JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-17

Study Completion Date

2023-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

NCT06850480

Reflux Esophagitis (RE)

RECRUITING PHASE3

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

NCT02028663

Erosive Esophagitis GERD

COMPLETED PHASE2

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

NCT02456935

Erosive Esophagitis

COMPLETED PHASE3

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

NCT05448001

Gastric Ulcer

COMPLETED PHASE3

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

NCT03006874

Erosive Esophagitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erosive Esophagitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group

JP-1366 20mg + Esomeprazole 40mg(placebo)

Group Type EXPERIMENTAL

JP-1366 20mg

Intervention Type DRUG

1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)

Active Comparative Group

JP-1366 20mg(placebo) + Esomeprazole 40mg

Group Type ACTIVE_COMPARATOR

Esomeprazole 40mg

Intervention Type DRUG

1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JP-1366 20mg

1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)

Intervention Type DRUG

Esomeprazole 40mg

1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, ≥ 19 years of age at the time of obtaining consent
2. Subjects who had experienced heartburn and regurgitation within 7 days prior to the screening visit, those whose severity and frequency of symptoms fall under the following (1) or (2)

⑴ Subjects who have experienced mild or more severe heartburn or regurgitation at least twice a week

⑵ Subjects who have experienced moderate or more severe heartburn or regurgitation at least once a week
3. Endoscopically confirmed grade A or higher erosive esophagitis as defined by †LosAngeles classification within 15 days, prior to randomization
4. Subjects who fully understand this study and voluntarily signed on the informed consent form

Exclusion Criteria

1. Subjects who can't undergo endoscopy
2. Medical History

º Subjects who have warning symptoms of the malignant gastrointestinal tract such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool. (except negative result for malignancy by endoscopy)

º Subjects with eosinophilic esophagitis (except negative result by esophageal biopsy)

º Subjects who have esophageal stenosis, gastroesophageal varices, Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding, or malignant tumor confirmed by EGD

º Zollinger-Ellison syndrome patients

º Subjects diagnosed with primary esophageal motility disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected with IBS in the last 3 months and with a current history of the disease including pancreatitis

º Subjects who have a history of gastric acid suppression surgery, gastrointestinal or esophageal surgery (except appendectomy, cholecystectomy, polypectomy)

º Subjects with a history of clinically significant hepatic, renal, cardiovascular, respiratory, endocrine, urinary, neuro-psychiatric, hemato-oncologic disorder

º Subjects who have a history of malignant tumor in 5 years at the time of screening. However, excluding subjects with malignant gastrointestinal cancer regardless of the period.
3. Laboratory Test

Screening laboratory test showing any of the following abnormal laboratory results:

º ALT or AST \> 2.0 x ULN

º ALP or GGT \> 2.0 x ULN

º Total bilirubin \> 2.0 x ULN

º eGFR\<70 mL/min/1.73 m2 (CKD-EPI formula)

º Positive result for Serological test (HBsAg, HCV Ab, HIV Ab, Syphilis reagin test)

º Clinically significant ECG abnormalities
4. Allergy and drug hypersensitivity

º Known hypersensitivity to the active ingredient or excipients of the investigational product

º Clinically significant allergies (except mild allergic rhinitis) or hypersensitivity history to drugs. (Aspirin, antibiotics, etc.)
5. Prohibited medication and therapy

º Subjects who take gastric acid suppressant like P-CAB, PPI within 2weeks prior to EGD of screening procedure

º Subjects who take medication (antacids, prokinetics, H2RA, etc.) related to reflux esophagitis more than 2times within 1week prior to EGD of screening procedure

º Subjects who need to take medication (aspirin, NSAIDs, etc.) that may cause an ulcer, during the study period

º Subjects who are on or need to be on the medications which categorized as contraindicated in this clinical trial.

However, subjects who are on the contraindicated medications can participate in the trial after the washout period of 2 weeks. If five times of the half-life of the contraindicated medications exceeds 2 weeks, the washout period will be set as five times of the half-life.
6. Pregnant and lactating women
7. Contraception Subjects who do not agree to use medically acceptable methods of contraception during the period study
8. Subjects with clinically significant psychiatric disorder and a history with a drug and alcohol abuse.
9. Subjects who are judged unsuitable to participate in the study in the opinion of the investigator

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No